COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,755 Articles (22,502 medRxiv, 8,253 bioRxiv)

Most recent first Previous |  Page 516: Articles 5151-5160  | Next

Modeling COVID-19 in different countries as sequences of SI waves
Janssen, R., Mimkes, J.
10.1101/2022.11.22.22282631 — Posted: 2022-11-22
Inability to work following COVID-19 vaccination among healthcare workers - an important aspect for future booster vaccinations
Reusch, J., Wagenhäuser, I., Gabel, A., Höhn, A., Lam, T.-T., Krone, L. B., Frey, A., Schubert-Unkmeir, A., Dölken, L., Frantz, S., Kurzai, O., Vogel, U., Krone, M., Petri, N.
10.1101/2022.11.21.22282594 — Posted: 2022-11-22
Cost of In-patient Management of Covid-19 Patients in a Tertiary Hospital in Kuwait
Muhammad Nur, A., Aljunid, S. M., Almari, M.
10.1101/2022.11.21.22282601 — Posted: 2022-11-22
Susceptibility-Weighted Magnetic Resonance Imaging Highlights Brain Alterations in COVID Recovered Patients.
Mishra, S. S., Hafiz, R., Misra, R., Gandhi, T. K., Prasad, A., Mahajan, V., Biswal, B. B.
10.1101/2022.11.21.22282600 — Posted: 2022-11-22
Temporal Associations of Plasma Levels of the Secreted Phospholipase A2 Family and Mortality in Severe COVID-19
Lu, E., Hara, A., Sun, S., Hallmark, B., Hallmark, J. M., Seeds, M. C., Watkins, J. C., McCall, C. E., Zhang, H. H., Yao, G., Chilton, F. H.
10.1101/2022.11.21.22282595 — Posted: 2022-11-22
In-depth characterization of the Syrian hamster as translational model for COVID-19 in humans
Castellan, M., Zamperin, G., Franzoni, G., Foiani, G., Zorzan, M., Drzewniokova, P., Mancin, M., Brian, I., Bortolami, A., Pagliari, M., Oggiano, A., Vascellari, M., Panzarin, V., Crovella, S., Monne, I., Terregino, C., De Benedictis, P., Leopardi, S.
10.1101/2022.11.22.517339 — Posted: 2022-11-22
Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Re-combinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial.
Liu, Y., Tan, L. H., Zhang, N., Zhang, Y., Mojares, Z. R.
10.1101/2022.11.20.22282565 — Posted: 2022-11-22
Nirmatrelvir treatment blunts the development of antiviral adaptive immune responses in SARS-CoV-2 infected mice
Fumagalli, V., Di Lucia, P., Rava, M., Marotta, D., Bono, E., Grassi, S., Donnici, L., Cannalire, R., Stefanelli, I., Ferraro, A., Esposito, F., Pariani, E., Inverso, D., Montesano, C., Delbue, S., Tramontano, E., De Francesco, R., Summa, V., Guidotti, L., Iannacone, M.
10.1101/2022.11.22.517465 — Posted: 2022-11-22
Use of whole genome sequencing to identify low-frequency mutations in COVID-19 patients treated with remdesivir
Nirmalarajah, K., Maguire, F., Yim, W., Aftanas, P., Li, A. X., Shigayeva, A., Yip, L., Zhong, X. Z., McGeer, A. J., Mubareka, S., Kozak, R.
10.1101/2022.11.20.22282552 — Posted: 2022-11-22
Lineage frequency time series reveal elevated levels of genetic drift in SARS-CoV-2 transmission in England
Yu, Q., Ascensao, J. A., Okada, T., The COVID-19 Genomics UK (COG-UK) consortium, , Boyd, O., Volz, E., Hallatschek, O.
10.1101/2022.11.21.517390 — Posted: 2022-11-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).